GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » Cyclically Adjusted Revenue per Share

NeoGenomics (STU:NG9) Cyclically Adjusted Revenue per Share : €3.47 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

NeoGenomics's adjusted revenue per share for the three months ended in Mar. 2024 was €1.140. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.47 for the trailing ten years ended in Mar. 2024.

During the past 12 months, NeoGenomics's average Cyclically Adjusted Revenue Growth Rate was 12.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 18.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of NeoGenomics was 24.50% per year. The lowest was 11.90% per year. And the median was 20.45% per year.

As of today (2024-06-02), NeoGenomics's current stock price is €12.50. NeoGenomics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €3.47. NeoGenomics's Cyclically Adjusted PS Ratio of today is 3.60.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NeoGenomics was 23.86. The lowest was 1.93. And the median was 6.43.


NeoGenomics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for NeoGenomics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Cyclically Adjusted Revenue per Share Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.96 1.97 2.57 3.18 3.53

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.21 3.28 3.56 3.53 3.47

Competitive Comparison of NeoGenomics's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, NeoGenomics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cyclically Adjusted PS Ratio falls into.



NeoGenomics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NeoGenomics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.14/131.7762*131.7762
=1.140

Current CPI (Mar. 2024) = 131.7762.

NeoGenomics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.283 100.560 0.371
201409 0.331 100.428 0.434
201412 0.325 99.070 0.432
201503 0.353 99.621 0.467
201506 0.359 100.684 0.470
201509 0.370 100.392 0.486
201512 0.411 99.792 0.543
201603 0.705 100.470 0.925
201606 0.725 101.688 0.940
201609 0.693 101.861 0.897
201612 0.582 101.863 0.753
201703 0.683 102.862 0.875
201706 0.698 103.349 0.890
201709 0.623 104.136 0.788
201712 0.648 104.011 0.821
201803 0.639 105.290 0.800
201806 0.643 106.317 0.797
201809 0.651 106.507 0.805
201812 0.697 105.998 0.867
201903 0.893 107.251 1.097
201906 0.880 108.070 1.073
201909 0.881 108.329 1.072
201912 0.906 108.420 1.101
202003 0.918 108.902 1.111
202006 0.716 108.767 0.867
202009 0.894 109.815 1.073
202012 0.833 109.897 0.999
202103 0.835 111.754 0.985
202106 0.770 114.631 0.885
202109 0.842 115.734 0.959
202112 0.908 117.630 1.017
202203 0.861 121.301 0.935
202206 0.954 125.017 1.006
202209 1.045 125.227 1.100
202212 1.050 125.222 1.105
202303 1.025 127.348 1.061
202306 1.082 128.729 1.108
202309 1.133 129.860 1.150
202312 1.133 129.419 1.154
202403 1.140 131.776 1.140

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


NeoGenomics  (STU:NG9) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NeoGenomics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.50/3.47
=3.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NeoGenomics was 23.86. The lowest was 1.93. And the median was 6.43.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


NeoGenomics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (STU:NG9) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

NeoGenomics (STU:NG9) Headlines

No Headlines